
Opinion|Videos|October 15, 2024
Patient Profile 1: A 70-Year-Old Man With PSMA-Positive mCRPC
Author(s)Oliver Sartor, MD
Key Takeaways
Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential radioligand therapy, considering factors such as disease progression, previous treatments, and overall health status in tailoring management strategies.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
From GSM guidance to HRT reform: A landmark year for women’s health
2
What’s new at Urology on the Beach 2026
3
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
4
Adjusted EV-302 analysis reinforces survival advantage of EV/pembrolizumab
5





















